UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile

The Journal of urology, 2015-04, Vol.193 (4), p.1114-1121

2015

Link zum Volltext

Verfügbarkeit prüfen

Informed consent in phase I clinical trials: Implications for trends in design

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14077-e14077

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial to assess the biologic effect of CBM588 ( Clostridium butyricum ) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2020-02, Vol.38 (6_suppl), p.TPS764-TPS764

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3174-TPS3174

2022

Link zum Volltext

Verfügbarkeit prüfen

The effect of megestrol acetate ± pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5597-5597

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1078-1078

2021

Link zum Volltext

Verfügbarkeit prüfen

Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.614-614

2024

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e13071-e13071

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS4606-TPS4606

2022

Link zum Volltext

Verfügbarkeit prüfen

Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA104-LBA104

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of PIPAC in patients with ovarian cancer with peritoneal metastases: A first-in-US phase I study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5554-5554

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.11505-11505

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.9055-9055

2020

Link zum Volltext

Verfügbarkeit prüfen

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.583-583

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1) in patients with metastatic breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1130-TPS1130

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.1053-1053

2022

Link zum Volltext

Verfügbarkeit prüfen

Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4510-4510

2022

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.371-371

2022

Link zum Volltext

Verfügbarkeit prüfen

Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.374-374

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study

Journal of clinical oncology, 2022-02, Vol.40 (4_suppl), p.125-125

2022

Link zum Volltext

Verfügbarkeit prüfen

Gene expression profiling of unresectable pancreatic cancer patients treated with gemcitabine, nab-paclitaxel, metformin, and dietary supplements (DS)

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.736-736

2020

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e17040-e17040

2016

Link zum Volltext

Verfügbarkeit prüfen

First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.4513-4513

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5542-5542

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(70)
Mit Volltextzugriff
(71)

Publikationsform

Sprache

Englisch
(73)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(4)
Science & Technology
(4)
Humans
(3)
1947
(2)
Adult
(2)
Aged
(2)
Congresses
(2)
Democracy
(2)
Female
(2)
Inde
(2)
India
(2)
India -- Politics And Government -- 1947- -- Congresses
(2)
Indien
(2)
Male
(2)
Middle Aged
(2)
Parliamentary Government
(2)
Political Process
(2)
Political Representation
(2)
Political Science
(2)
Political Science / Political Process / General
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile

Informed consent in phase I clinical trials: Implications for trends in design

A phase I trial to assess the biologic effect of CBM588 ( Clostridium butyricum ) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC)

A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma

The effect of megestrol acetate ± pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer

Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial

Extended follow-up report of a randomized phase II trial comparing gemcitabine and cisplatin with or without berzosertib in patients with advanced urothelial carcinoma

Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer

A phase I trial to evaluate the biologic effect of CBM588 ( Clostridium butyricum ) in combination with cabozantinib plus nivolumab for patients with metastatic renal cell carcinoma (mRCC)

Effect of CBM588 in combination with cabozantinib plus nivolumab for patients (pts) with metastatic renal cell carcinoma (mRCC): A randomized clinical trial

Safety and efficacy of PIPAC in patients with ovarian cancer with peritoneal metastases: A first-in-US phase I study

A phase II study of cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas

Phase I study of TRC102 in combination with cisplatin and pemetrexed in patients with advanced solid tumors/Phase II study of TRC102 with pemetrexed in patients with mesothelioma refractory to pemetrexed and cisplatin or carboplatin

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer

Phase I/II first-in-human CAR T–targeting MUC1 transmembrane cleavage product (MUC1) in patients with metastatic breast cancer

Phase I study combining pembrolizumab and aromatase inhibitor in patients with metastatic hormone receptor–positive breast cancer

Characterization of the microbial resistome in a prospective trial of CBM588 in metastatic renal cell carcinoma (mRCC) offers mechanism for interplay between antibiotic (abx) use and immune checkpoint inhibitor (ICI) activity

Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: A randomized phase Ib study and the evolution of the functionality of microbial communities with treatment

Intestinal microbiome associated with development of grade 3/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N/I) and probiotic support: Results from a phase Ib study

Safety and efficacy of pressurized intraperitoneal aerosolized chemotherapy in appendiceal and colorectal cancer patients with peritoneal carcinomatosis: A first-in-US phase I study

Gene expression profiling of unresectable pancreatic cancer patients treated with gemcitabine, nab-paclitaxel, metformin, and dietary supplements (DS)

A phase I study of a p53MVA vaccine in combination with gemcitabine (GEM) in recurrent ovarian cancer (OC)

First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma

A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected frα-positive solid tumors: Results in the ovarian cancer (EC) cohort

Suchergebnisse filtern